Document:

Amended Patent Assignment

 ORCHID BIOSCIENCES, INC. HAS REQUESTED THAT THE MARKED PORTIONS OF THIS DOCUMENT BE ACCORDED 406 CONFIDENTIAL
TREATMENT PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  
 [*] CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS. 
  
 Exhibit 10.25 
  
 Agreement to Amend Patent Assignment and License Agreement 
  
 DATED JULY 7, 2003 (“AMENDMENT DATE”) 
  

			
		
	 BETWEEN:
	  	Diatech Pty Ltd (ACD 069052 197) a corporation whose legal address is c/o School of Life Sciences, Queensland University of Technology, 2 George Street, Brisbane, Queensland 4000
(“DIATECH”), GeneCo Pty Ltd (CAN 010 737 603) a corporation, whose legal address is 4th Floor, O
Block Podium, Queensland University of Technology, 2 George Street, Brisbane, Queensland 4000, Australia (“GENECO”) and Queensland University of Technology, a body corporate constituted pursuant to the provisions of the Queensland
University of Technology Act 1998 (Qld) whose legal address is 2 George Street, Brisbane, Queensland 4000 Australia (“QUT”)
		
	 	  	(together the “ASSIGNORS”)
		
	 AND
	  	ORCHID BIOSCIENCES, INC., a Delaware corporation having a principal place of business at 4390 U.S. Route One, Princeton, NJ 08540
		
	 	  	(“ORCHID”)

  
 AGREE AS FOLLOWS: 

 
 1. BACKGROUND 
  
 1.1 ASSIGNORS assigned to AFFYMETRIX, INC. (“ AFFYMETRIX”) certain rights relating to a Patent entitled
“Detection of a Nucleic Acid Sequence or a Change Therein” pursuant to a Patent Assignment and License Agreement dated February 28, 2000 and effective as of March 20, 2000 (“Original Agreement”). Those rights are defined as
“ASSIGNED PATENT RIGHTS” in the Original Agreement. 
  
 1.2 With the consent of ASSIGNORS, ORCHID thereafter acquired from AFFYMETRIX the ASSIGNED PATENT RIGHTS and assumed all of AFFYMETRIX’s rights and obligations under the Original Agreement, under an Assignment Agreement dated as of
July 18, 2001 (“Assignment Agreement”). subject to the terms and conditions of the Original Agreement. 
  
 1.3 ORCHID and ASSIGNORS have agreed to amend certain payment and other obligations under the Original Agreement and to otherwise amend and restate the
Original Agreement in its entirety and to reaffirm their continuing obligations thereunder as set forth herein. 
  
 2. AMENDMENT 
  
 2.1 ASSIGNORS and Orchid agree effective as of the AMENDMENT DATE, the provisions of the Original Agreement are varied as set out in Schedule 1 to this
Agreement. Subject to the amendments specified in Schedule 1 to this Agreement, the parties reaffirm the provisions of the Original Agreement as between them following the execution by ORCHID and AFFYMETRIX of the Assignment Agreement. 

 3. APPLICABLE LAW 
  
 3.1 This Agreement will be construed, interpreted, and applied in accordance with the laws of the State of California in the United States. 
  
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement in
duplicate originals by their duly authorized officers or representatives. 
  

	By:	

  

							
	 DIATECH
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

			
	 GENECO
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

							
	 QUT
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	

	 Name:
	 	  

	 	 Name:
	 	

	 Title:
	 	  

	 	 Title:
	 	

	 Date:
	 	  

	 	 Date:
	 	

			
	 ORCHID BIOSCIENCES, INC.
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

 SCHEDULE 1 
 AMENDMENTS TO ORIGINAL AGREEMENT 
  
 Patent Assignment and License Agreement 
  
 Dated:
February 28, 2000 
  

			
		
	BETWEEN:	  	Diatech Pty Ltd (ACD 069052 197) a corporation whose legal address is c/o School of Life Sciences, Queensland University of Technology, 2 George Street, Brisbane, Queensland 4000
(“DIATECH”), GeneCo Pty Ltd (CAN 010 737 603) a corporation, whose legal address is 4th Floor, O
Block Podium, Queensland University of Technology, 2 George Street, Brisbane, Queensland 4000, Australia (“GENECO”) and Queensland University of Technology, a body corporate constituted pursuant to the provisions of the Queensland
University of Technology Act 1998 (Qld) whose legal address is 2 George Street, Brisbane, Queensland 4000 Australia (“QUT”)
		
	 	  	 (together the “ASSIGNORS”)

		
	AND:	  	ORCHID BIOSCIENCES, INC., a Delaware corporation having a principal place of business at 4390 U.S. Route One, Princeton, NJ 08540
		
	 	  	ORCHID

  
 AGREE AS FOLLOWS: 

 
 1. BACKGROUND 
  
 1.1 GENECO is the current owner of a Patent entitled “Detection of a Nucleic Acid Sequence or a Change Therein”
and ASSIGNED PATENT RIGHTS as defined below. 
  
 1.2 GENECO
granted to QUT a world-wide exclusive license of certain of the ASSIGNED PATENT RIGHTS (attached as Exhibit A), and QUT granted to DIATECH a world-wide exclusive sublicense of those same rights (attached as Exhibit B). 
  
 1.3 ASSIGNORS assigned the ASSIGNED PATIENT RIGHTS to AFFYMETRIX, who wished
to acquire the ASSIGNED PATENT RIGHTS for the purpose of undertaking development and to manufacture, use, and distribute certain reagents. 
  
 1.4 AFFYMETRIX, with the consent of GENECO, QUT and DIATECH, assigned the ASSIGNED PATENT RIGHTS TO ORCHID. 
  
 2. DEFINITIONS 
  
 2.1 “AFFYMETRIX” means AFFYMETRIX Inc., a Delaware corporation having a principal place of business at 3380
Central Expressway, Santa Clara, CA 95051. 

 2.2 “ASSIGNED PATENT RIGHTS” means the patents, patent applications and license agreements
(including all rights of any party contained therein) set forth on Exhibit C and assigned to ORCHID pursuant to Section 3 and the Patent Assignment attached as Exhibit D, which GENECO executed on the EFFECTIVE DATE, including without limitation, the
underlying inventions to the patents and patent applications, and any and all Letters Patents whether U.S. or foreign that are or may be granted therefrom including without limitation any extensions, continuations, continuations-in-part, divisions,
reissues, improvements and renewals thereof, or other equivalents thereof, and trade secrets and know-how related thereto which are in the possession of ASSIGNORS as of the EFFECTIVE DATE, and further, all rights and privileges pertaining to the
ASSIGNED PATENT RIGHTS including without limitation the right, if any, to claim the right to priority thereto and to sue or bring other actions for past, present and future infringement thereof. 
  
 2.3 “AFFILIATE” means any corporation or other business entity in
which ORCHID owns or controls, directly or indirectly, at least ten percent (10%) of the outstanding stock or other voting rights entitled to elect directors or in which ORCHID is owned or controlled directly or indirectly by at least ten percent
(10%) of the outstanding stock or other voting rights entitled to elect directors; but in any country where the local law does not permit foreign equity participation of at least ten percent (10%), then an “AFFILIATE” includes any company
in which ORCHID owns or controls, or is owned or controlled by, directly or indirectly, the maximum percentage of outstanding stock or voting rights permitted by local law. 
  
 2.4 “EFFECTIVE DATE” means March 20, 2000 being the date on which GENECO notified AFFYMETRIX in writing that the
R&D syndication established by the TRANSACTION DOCUMENTS had wound-up and that GENECO had fulfilled all of its obligations under and to all parties to the TRANSACTIONS DOCUMENTS. 
  
 2.5 “TERRITORY” means Australia. 
  
 2.6 “MEMBER(S)” shall mean members of the CRC that have signed an agreement with CRC for such membership.

  
 2.7 “TRANSACTION DOCUMENTS” means the following
agreements, complete copies of which were provided to ORCHID for due diligence purposes prior to the execution of this Agreement, which established the R&D syndication knows as the Cystic Fibrosis Joint Venture: 
  
 (a) License Agreements dated 30 June 1994 between: 
  
 (i) GENECO and Australasian Drug Development Limited (“ADDL”) and

  
 (ii) Auspep Pty Ltd and ADDL. 

 (b) Procedures Memorandum dated 30 June 1994 between all parties to the Cystic Fibrosis Joint Venture.

  
 (c) License, Research and Commercialisation Agreement dated 30
June 1994 between ADDL, GENECO, Auspep Pty Ltd, and each of Radtel 1 Pty Ltd, Radmed 2 Pty Ltd and Radtel 3 Pty Ltd (together “Investor”). 
  
 (d) Deposit Agreement dated 30 June 1994 between Bankers Trust Australia Limited (“Lender”), ADDL and GENECO. 
  
 (e) Company Put Option Agreements dated 30 June 1994 between: 
  
 (i) GENECO, ADDL, Edingbay Pty Ltd, the Lender and BT Financial Management
Pty Ltd (“Manager”); 
  
 (ii) GENECO, ADDL, Twentieth
Apelda Pty Ltd, the Lender and the Manager; and 
  
 (iii) GENECO,
ADDL, Edzell Holdings Pty Ltd, the Lender and the Manager. 
  
 3. ASSIGNMENT

  
 3.1 Assignment. On the EFFECTIVE DATE the
ASSIGNORS hereby jointly and severally assign, transfer and convey to ORCHID all of ASSIGNORS’ right, title, and interest throughout the world in and to said ASSIGNED PATENT RIGHTS. 
  
 3.2 Further Assignment. On the EFFECTIVE DATE the ASSIGNORS jointly and severally further assign to and empower
ORCHID, its successors, assigns or nominees, all rights to make applications for patents or other forms of protection for ASSIGNED PATENT RIGHTS, as well as to claim and receive the benefit of the right of priority provided by the International
Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it, and the right to invoke and claim such right of priority without further written or oral authorization. 
  
 3.3 Authorization of Patent and Trademark Office to Record. ASSIGNORS
jointly and severally further agree that the agreement attached as Exhibit D, which GENECO must execute on the EFFECTIVE DATE, shall be deemed a full legal and formal equivalent of any assignment, consent to file or like document which may be
required in any country for any purpose regarding the subject matter hereof, as well as constituting proof of the right of ORCHID or its successors, assigns or nominees to apply for patent or other proper protection for said inventions, and to claim
the aforesaid benefits of the right of priority provided by the International Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it. 

 3.4 Further Assurances. ASSIGNORS jointly and severally agree to take such further actions and to
execute such documents as ORCHID may reasonably request to effect or confirm the conveyance to ORCHID of the ASSIGNED PATENT RIGHTS and any improvements thereunder. 
  
 4. GRANT OF LICENSES TO THE TECHNOLOGY 
  
 4.1 Research License. Subject to the terms and conditions of this Agreement, ORCHID hereby grants to the ASSIGNORS a non-exclusive,
non-transferable (except as permitted by this Agreement), fully-paid right to use the ASSIGNED PATENT RIGHTS solely for the purpose of conducting internal non-commercial, non-profit research purposes, solely in the TERRITORY. Such license shall be
sublicensable only by DIATECH and only to MEMBERS as approved by ORCHID pursuant to Section 4.3. 
  
 4.2 Genotyping Service License. Subject to the terms and conditions of this Agreement, ORCHID hereby grants to DIATECH, with the right to
sublicense only to CRC members as approved by ORCHID pursuant to Section 4.3, a non-transferable (except as permitted by this Agreement), non-exclusive, fully-paid right to use the ASSIGNED PATENT RIGHTS to offer genotyping services (but only
genotyping services that do not use micro-arrays) only I the TERRITORY and provided that DIATECH and the MEMBERS only offer and perform such services on genetic materials originating or derived solely in the TERRITORY. 
  
 4.3 Member Approved Rights. A list of MEMBERS approved by ORCHID to
receive a sublicense from DIATECH under Sections 4.1 and 4.2 above is attached as Exhibit E. DIATICH may make additions to this list by written consent which shall not be unreasonably withheld (for the avoidance of doubt, the withholding of consent
regarding a competitor of ORCHID shall not be considered unreasonable). Such request shall designate the name of the member, any affiliates of the member who will have LICENSED RIGHTS (defined as any rights licensed to a member under Sections 4.1 or
4.2 of this agreement) under this agreement through their affiliation with the member if such member is approved by ORCHID, the address of such parties, a brief description of the Business of the member, and a general description of the research to
be performed. ORCHID shall have 30 days from a request to add to Exhibit E to respond to such request with its consent or denial of such request. If ORCHID fails to respond within 30 days, the member shall be deemed to have been approved and shall
be added to the list. Upon the grant of a sublicense under Sections 4.1 and 4.2 to a member, such member shall sign a license agreement with DIATECH that is at least as protective of ORCHID as this agreement. Such license agreement shall also
provide that in the event of a material breach of the license agreement that is not corrected within thirty (30) days of written notice to the member by ORCHID. ORCHID or DIATECH shall have the right to immediately terminate the sublicense. Each
sublicense granted by DIATECH to a MEMBER pursuant to this Section 4 above shall continue for the term of this Agreement unless ORCHID provides notice to DIATECH of its withdrawal of consent for any sublicense to any specific MEMBER prior to
November 1 of any year due to the failure of that specific MEMBER to rectify a material breach. ORCHID shall be provided a copy of each sublicense granted by DIATECH under this Agreement. 

 4.4 Right of First Refusal. The ASSIGNORS, and their sublicensees, grant to ORCHID the first right
to license any patents, patent applications or other related rights arising from their use of the ASSIGNED PATENT RIGHTS pursuant to Section 4.1, 4.2 and 4.3. ORCHID shall be notified of such rights prior to their being offered to any third party.

  
 5. PAYMENTS 
  
 5.1 On the AMENDMENT DATE, ORCHID shall pay to QUT and DIATECH a
non-refundable payment of US$375,000.00 as follows: 
  
 (a) US$187,500.00 to QUT; and 
  
 (b)
US$187,500 to DIATECH. 
  
 5.2 In addition to the payments
referred to in Section 5.1, ORCHID shall pay to ASSIGNORS an aggregate non-refundable sum of US$600,000 in four equal annual installments of US$150,000 each within fourteen (14) days of each of the four anniversary dates following the AMENDMENT
DATE. ORCHID shall pay each installment to QUT and DIATECH in equal shares (50% each). 
  
 5.3 ORCHID will make the payments referred to in Sections 5.1 and 5.2 by cheques, or by other means if mutually agreed by the parties, to the ASSIGNORS forwarded to each party at the address shown in Section 14
(Notices). 
  
 5.4 From the EFFECTIVE DATE until 5 years after the
expiration of this Agreement, the parties shall keep true and complete records, including all certifications, advice or any correspondence, related to any taxation (or lack thereof) by any government or governmental agency resulting from any
payments made by one party to another under this Agreement. 
  
 5.5 ORCHID must provide the ASSIGNORS upon request written verification of the amount of any tax paid by it in the US relating to any payments made by ORCHID to the ASSIGNORS under this Agreement, to enable the ASSIGNORS to clam if
appropriate, a corresponding tax credit in Australia. 
  
 6. LIFE OF THE
AGREEMENT 
  
 6.1 Unless otherwise terminated by the
operation of law or by acts of the parties in accordance with the terms of this Agreement, this Agreement will be in force from the EFFECTIVE DATE and will remain in effect for the life of the last-to-expire patent licensed under this Agreement.

 6.2 ASSIGNORS may terminate this Agreement immediately on written notice to ORCHID if ORCHID fails to pay
any sum due to any of the ASSIGNORS under this Agreement and the amount remains outstanding for a period of 90 days after the receipt of notice from ASSIGNORS of such failure to pay. 
  
 6.3 ORCHID may terminate any licenses granted under this Agreement as to any of the ASSIGNORS if any such party materially
breaches a license granted by this agreement and fails to cure such breach within 90 days of notice of such breach by the other party. 
  
 6.4 If the ASSIGNORS terminate this Agreement pursuant to Section 6.2, and as at the date of such termination the total payments that have been made by
ORCHID to ASSIGNORS pursuant under Section 5.1 and 5.2 are less than [*], then ORCHID must re-assign to each of the ASSIGNORS their ASSIGNED PATENT RIGHTS in their entirely and at no cost to the ASSIGNORS except as agreed by the ASSIGNORS.

  
 6.5 Any termination of this Agreement shall not affect the
rights and obligations set forth in the following articles: Section 6.4, Sections 9 – 12, Section 14, Sections 16 – 17, and Section 20. 
  
 6.6 Any termination of this Agreement will not relieve ORCHID of its obligation to pay any moneys due to owing at the time of such termination and will
not relieve any obligations, of either party to the other party, established prior to termination. 
  
 7. USE OF NAMES AND TRADEMARKS 
  
 7.1 Nothing contained in this Agreement will be construed as conferring any right to use in advertising, publicity or other promotional activities, any name, trademark, trade name, or other designation of either party hereto by the other
(including any contraction, abbreviation, or simulation of any of the foregoing). 
  
 8. REPRESENTATION AND WARRANTIES 
  
 8.1 Each of
the ASSIGNORS jointly and severally warrants to ORCHID that as at the EFFECTIVE DATE is has the lawful right to assign the relevant ASSIGNED PATENT RIGHTS to ORCHID and that nothing in, or related to, the TRANSACTION DOCUMENTS prevents ASSIGNORS
from assigning all rights to the ASSIGNED PATENTS as contemplated by this Agreement. 
  
 8.2 Each of the ASSIGNORS severally warrants that as at the EFFECTIVE DATE: 
  
 (a) no licenses currently exist to the ASSIGNED PATENT RIGHTS; and 
  
 (b) any prior licenses to such rights have been terminated or assigned to ORCHID. 

 8.3 Nothing in this Agreement is or will be construed as: 
  
 (a) A warranty or representation by ASSIGNORS as to the validity,
enforceability or scope of any ASSIGNED PATENT RIGHTS; or 
  
 (b)
A warranty or representation that anything made, used, sold, or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents of third parties; or 
  
 (c) Conferring by implication, estoppel, or otherwise any rights under any
patents of ASSIGNORS other than ASSIGNED PATENT RIGHTS as defined herein, regardless of whether such patents are dominant or subordinate to ASSIGNED PATENT RIGHTS; or 
  
 (d) An obligation to furnish any know how, not provided in ASSIGNED PATENT RIGHTS. 
  
 9. LIABILITY LIMITATION 
  
 9.1 IN NO EVENT WILL ANY PARTY TO THIS AGREEMENT BE LIABLE FOR ANY INCIDENTALY, SPECIAL OR CONSEQUENTIAL DAMAGES, INCLUDING
BUT NOT LIMITED TO LOSS OF REVENUE, PROFITS, GOODWILL OR REPUTATION, BARGAIN OR OPPORTUNITIES, RESULTING FROM EXERCISE OF THE ASSIGNMENT OF THE ASSIGNED PATENT RIGHTS OR FROM ORCHID’S SALE OR TRANSFER OF ANY PRODUCT OR SERVICE THAT RESULTS OR
IS DEVELOPED FROM, OR INCORPORATES ANY COMPONENT OF THE ASSIGNED PATENT RIGHTS OR THE USE BY ANY THIRD PARTY OF PRODUCTS OR SERVICES. 
  
 10. PATENT INFRINGEMENT 
  
 10.1 ORCHID is responsible for and will pay all patent prosecution expenses including all filing and associated fees after the EFFECTIVE DATE of this
Agreement, and all such expenses incurred before the EFFECTIVE DATE of the Agreement for applications filed in AT, BE, CH, DK, ES, LU, NL and SE. ORCHID will control the prosecution of all applications and post-issuance matters after the EFFECTIVE
DATE of this Agreement. 
  
 10.2 ASSIGNORS will cooperate,
including being joined as a party if reasonably necessary (with all related costs to be paid by ORCHID), with ORCHID in litigation instituted with regard to the ASSIGNED PATENT RIGHTS but at the expense of ORCHID. Such litigation will be controlled
by ORCHID. The ASSIGNORS will use their respective best efforts to obtain the cooperation, in such action of any inventors or other persons associated with the ASSIGNED PATENT RIGHTS. 

 11. INDEMNIFICATION 
  
 11.1 ORCHID will, and will cause its affiliates, to indemnify, hold harmless, and defend ASSIGNORS, its officers, employees, and agents; sponsor(s) of the
research that led to the ASSIGNED PATENT RIGHTS; and the inventors of any patents and patent applications in ASSIGNORS’ PATENT RIGHTS and their employers against any and all claims, suits, losses, damages, costs, fees, and expenses resulting
from or arising out of exercise of the ASSIGNED PATENT RIGHTS or any license, including, but not be limited to, any product liability, provided that (i) ORCHID is promptly notified in writing of such claim or suit, (ii) ORCHID has the sole control
of and must conduct the defense and/or settlement thereof, and (iii) ASSIGNORS furnish to ORCHID, on request, information available to ASSIGNORS for such defense. However, ORCHID is in no way authorized to agree to any settlement, compromise or the
like which would compromise the ASSIGNED PATENT RIGHTS and/or would require that ASSIGNORS make any payment, or bear other obligations beyond those required by this Agreement. 
  
 12. ARBITRATION AND DISPUTES 
  
 12.1 Except that either party may seek urgent injunctive or similar relief from a court, any dispute, controversy or claim arising out of or in relation
to this Agreement or at law, or the breach, termination or invalidity thereof, that cannot be settled amicably by agreement of the parties hereto, may be finally settled by arbitration in accordance with the World Intellectual Property Organisation
Arbitration Rules by one or more arbitrators appointed in accordance with said rules; provided, however, that arbitration proceedings may not be instituted until the party alleging breach of this Agreement by the other party has given the other
party not less than 90 days to remedy any alleged breach and the other party has failed to do so. The place of arbitration shall be the State of California in the United States. The parties shall share the cost of the arbitrator equally but each
party will bear their own costs of such arbitration including their own attorney’s fees. 
  
 13. ASSIGNMENT 
  
 13.1
This Agreement is binding upon and shall inure to the benefit of the parties, their successors and assigns. This Agreement may be assigned by each party with written consent of all other parties, which shall not be unreasonably withheld provided at
least thirty (30) days notice has been given by the party wishing to assign, except that no such consent from ASSIGNORS shall be necessary for an assignment by ORCHID in the event of a sale or transfer of all or substantially all of its assets
whether by sale, merger or otherwise. 

 14. NOTICES 
  
 14.1 All notices under this Agreement will be deemed to have been fully given when done in writing and deposited in the United States mail or Australian
mail as the case may be, registered or certified, and addressed as follows: 
  

			
	 To ASSIGNORS:
	  	 
	 	  	GENECO
	 	  	C/o Office of Commercial Services
	 	  	Queensland University of Technology
	 	  	GPO Box 2434
	 	  	BRISBANE QLD 4001
	 	  	Australia
	 	  	Fax: +617 3864 1512
	 	  	Attn.: The Company Secretary
		
	 	  	AND
		
	 	  	Diatech
	 	  	C/o School of Life Sciences
	 	  	Queensland University of Technology
	 	  	2 George Street
	 	  	BRISBANE QLD 4000
	 	  	Australia
	 	  	Fax: +617 3864 1534
	 	  	Attn: The Company Secretary
		
	 	  	AND
		
	 	  	QUT
	 	  	C/o Office of Commercial Services
	 	  	Queensland University of Technology
	 	  	GPO Box 2434
	 	  	BRISBANE QLD 4001
	 	  	Australia
	 	  	Fax: +617 3864 1512
	 	  	Attn.: Manager, Office of Commercial Services

  
 Any party may change
its address upon written notice to the other parties. 
  
 15. WAIVER

  
 15.1 The failure of either party to assert a right
hereunder or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. 
  
 15.2 None of the terms, covenants, and conditions of this Agreement can be
waived except by the written consent of the party waiving compliance. 

 16. CONFIDENTIALITY 
  
 16.1 ORCHID and ASSIGNORS respectively will hold each party’s proprietary business, terms of this Agreement, patent prosecution material, trade
secrets and know-how, and technical information and other proprietary information in confidence and against disclosure to third parties with at least the same degree of care as it exercises to protect its own data and license agreements of a similar
nature. 
  
 16.2 Nothing contained herein will in any way restrict
or impair the right of ORCHID or ASSIGNORS to use, disclose, or otherwise deal with any information or data which: 
  
 (a) at the time of disclosure to a receiving party is generally available to the public or thereafter becomes generally available to the public by
publication or otherwise through no act of the receiving party: 
  
 (b) the receiving party can show by written record was in its possession prior to the time of disclosure to it hereunder and was not acquired directly or indirectly from the disclosing party; 
  
 (c) is independently made available to the receiving party without
restrictions as a matter of right by a third party; 
  
 (d) is
subject to disclosure under the California Public Records Act, any applicable stock exchange or other requirements of law; 
  
 (e) is provided in confidence to a party’s professional advisers for the purposes of seeking professional advice; or 
  
 (f) is required to be disclosed to prosecute or defend any claim, action,
proceeding or demand. 
  
 16.3 It is understood that ASSIGNORS
will be free to release to the inventors and senior administrators employed by ASSIGNORS the terms and conditions of this Agreement upon their request. If such release is made, ASSIGNORS will inform such employees of the confidentiality obligations
set forth above and will request that they do not disclose such terms and conditions to others. 
  
 16.4 ORCHID and ASSIGNORS agree to destroy or return to the disclosing party proprietary information received from the other in its possession within
fifteen (15) days following the effective date of termination of this Agreement. However, each party may retain one copy of proprietary information of the other solely for archival purposes in non-working files for the sole purpose of verifying the
ownership of the proprietary information, provided such proprietary information, provided such proprietary information will be subject to the confidentiality provision set forth in Section 16.1. ORCHID and ASSIGNORS agree to provide each other,
within thirty (30) days following termination of this Agreement, with a written notice that proprietary information has been returned or destroyed. 

 16.5 The terms of this Section 16 (Confidentiality) will expire in five (5) years from the official date
of termination of this Agreement. 
  
 17. ATTORNEY’S FEES 

 
 17.1 In the event of legal action, other than arbitration conducted in
accordance with Section 12, taken by a party against the other arising out of this Agreement, the prevailing party will be entitled to reasonable attorney’s fees in addition to costs and necessary disbursements. 
  
 18. FORCE MAJEURE 
  
 18.1 The parties to this Agreement shall be excused from any performance required hereunder if such performance is rendered
impossible or unfeasible due to any catastrophes or other major events beyond their reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other
serious labor disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the parties’ respective obligations hereunder will resume. 
  
 19. SEVERABILITY 
  
 19.1 The provisions of this Agreement are severable, and in the event that any provision of this Agreement will be determined to be invalid or
unenforceable under any controlling body of law, such invalidity or enforceability will not in any way affect the validity or enforceability of the remaining provisions hereof. 
  
 20. APPLICABLE LAW 
  
 20.1 THIS AGREEMENT WILL BE CONSTRUED, INTERPRETED, AND APPLIED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, U.S.A. QUESTIONS CONCERNING THE
LAW AND EFFECT OF THE ASSIGNORS’ PATENT RIGHTS WILL BE DETERMINED BY THE LAW OF THE COUNTRY IN WHICH THE RELEVANT PATENT WAS GRANTED. 
  
 21. SCOPE OF AGREEMENT 
  
 21.1 This Agreement incorporates the entire agreement between the parties with respect to the subject matter hereof, and this Agreement may be altered or
modified only by written amendment duly executed by the parties hereto. 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate originals by their duly
authorized officers or representatives. 
  

	By:	

  

							
	 DIATECH
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

			
	 GENECO
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

			
	 QUT
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

			
	 ORCHID BIOSCIENCES, INC.
	 	 	 	 
				
	 By:
	 	  

	 	 By:
	 	  

	 Name:
	 	  

	 	 Name:
	 	  

	 Title:
	 	  

	 	 Title:
	 	  

	 Date:
	 	  

	 	 Date:
	 	  

 Exhibit A 
  

QUT License 
  

 E-1 

 Exhibit B 
  

Diatech License 
  

 E-2 

 Exhibit C 
  

Assigned Patents Rights 
  
  
 [*] 
  

 Exhibit D 
  

Patent Assignment Document 
 ASSIGNMENT 

 
 WHEREAS, GeneCo Pty Ltd, 4th Floor, O Block Podium, Queensland University of Technology, 2 George Street, Brisbane, Queensland 4000, Australia, hereinafter referred to as
“Assignor”, is the owner of rights in certain new and useful improvements as described and set forth in the applications for United States Letters Patent and corresponding filings worldwide listed in Attachment 1. 
  
 WHEREAS, Affymetrix, Inc., a corporation of the state of Delaware, located at 3380 Central
Expressway, Santa Clara, CA 95051, hereinafter referred to as “ASSIGNEE”, is desirous of acquiring an interest in the invention and applications and in any Letters Patents and Registrations that my be granted on the same; 
  
 For good and valuable consideration, receipt of which is hereby acknowledged by Assignor,
Assignor has assigned, and by these presents does assign to Assignee all Assignor’s right, title and interest in and to the invention, including all patent filings listed in Attachment 1, all counterparts deriving priority therefrom (including
patent, utility model and industrial designs), and in and to an Letters Patent and Registrations which may hereafter be granted on the same in the United States and all countries throughout the world, and to claim the priority from the applications
as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee’s successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignor had this assignment not
been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof. 
  
 Assignor further agrees that Assignor will, without charge to Assignee, but at
Assignee’s expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including
patent applications and instruments of transfer and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title
thereto in Assignee, or Assignee’s successors and assigns. 
  
 IN TESTIMONY
WHEREOF, this Assignment is executed 
  

			
	 Signed:
	 	  

	 Name:
	 	  

	 Position: Director

	 Assignor: GeneCo Pty Ltd.

  

 E-4 

			
	 Signed:
	 	  

	 Name:
	 	  

	 Position: Director/Secretary

	
	 Assignor: GeneCo Pty Ltd.

  

			
	THE COMMON SEAL of GENECO	 	)
	PTY LTD was affixed to this Agreement	 	)
	in accordance with its Constitution in	 	)
	The presence of:	 	)

  

			
	 Signed:
	 	  

	 Name:
	 	  

	 Position: Director/Secretary

	
	 Assignee: Affymetrix, Inc.

  

			
	STATE OF CALIFORNIA	 	)
	 	 	)         ss.
	COUNTY OF	 	)

  
 On                    , before me,
                    , personally appeared            personally known to me
(or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument, and acknowledged to me that he/she executed the same in his/her authorized capacity, and that by his/her signature on the
instrument th person, or the entity upon behalf of which the person acted, executed the instrument. 
  
 WITNESS my hand and official seal. 
  

	
	  

	 NOTARY PUBLIC

  
 My Commission
Expires:                         
  

 E-5 

 Attachment 1 to Patent Assignment Document 
  
 Assigned Patents Rights 
  
  
 [*] 
  

 Exhibit E 
  

List of Approved CRC Members 
  
  
 [*] 
  

 E-7Exclusive Patent License Agreement

 Exhibit 10.26 
  
 EXCLUSIVE PATENT LICENSE AGREEMENT 
  
 This Exclusive Patent License Agreement (this “Agreement”) is made effective as of the Effective Date (as defined
below) by and between Orchid BioSciences, Inc. (“ORCHID”), a Delaware corporation and Saint Louis University, a non-profit organization organized and existing under the laws of the State of Missouri (“SLU”). ORCHID and SLU are
hereinafter referred to collectively as the “Parties.” 
  
 RECITALS: 
  
 A. WHEREAS, SLU is the owner
of U.S. Patent No. 5,846,710, entitled Method for the Detection of Genetic Diseases and Gene Sequence Variations by Single Nucleotide Primer Extension, issue date December 8, 1998 (the “‘710 Patent or the “Licensed
Patent”). 
  
 B. WHEREAS, ORCHID commenced a declaratory
judgment action in the United States District Court for the Southern District of California that was transferred to the United States District Court for the Eastern District of Missouri (Civil Action No. 4:02CV00179JCH, U.S.D.C., E.D. of MO) against
SLU in connection with the parties’ rights and obligations with respect to the ‘710 Patent (the “Action”). 
  
 C. WHEREAS, SLU filed a counterclaim against ORCHID alleging patent infringement of the ‘710 Patent. 
  
 D. WHEREAS, the Parties have entered into that certain Settlement Agreement
dated August 6th, 2002 (the “Settlement Agreement”). All capitalized terms not defined herein shall have the meaning as set forth in the Settlement Agreement. 
  
 E. WHEREAS, Pursuant to the terms and conditions of the Settlement Agreement, SLU assigned, transferred and set over to
ORCHID its entire right, title and interest in and to the ‘710 Patent. 
  
 F. WHEREAS, NIH failed to issue its approval to the assignment and transfer of the ‘710 Patent to ORCHID as requested by the terms of the Settlement Agreement, therefore rendering the ‘710 Patent assignment
and transfer void, and thereby requiring SLU, under the terms of the Settlement Agreement, to grant a license to ORCHID as set forth therein. 
  
 AGREEMENT 
  
 NOW THEREFORE, in consideration of the foregoing, and the mutual promises, covenants, and agreements hereinafter set forth and each act to be performed
hereunder, and other good and valuable consideration (the receipt, adequacy and sufficiency of which are hereby acknowledged by the Parties by their execution hereof), the Parties agree as follows: 

 1. Grant of License and Duration 
  
 1.1 License Grant. Effective as of February 25, 2003 (the “Effective Date”), SLU hereby grants to ORCHID,
and ORCHID accepts from SLU, an exclusive (subject only to the rights of the National Institute of Health (“NIH”), the Existing Third Party Agreements (as described in Section 3.4 below) and SLU’s right to use the Licensed Patent
solely for internal research and development purposes), worldwide license, including the right to grant sublicenses to all or any portion of its rights hereunder, under the Licensed Patent, to research, develop, make have made, use, have used, sell,
offer for sale, have sold, import, have imported, export and have exported Licensed Products, for any and all uses, and to otherwise commercially exploit such Licensed Patent for any and all uses subject to the other terms and conditions of this
Agreement. In consideration of the rights granted hereunder, ORCHID shall make the payments to SLU described in Section 5 of this Agreement. For purposes of this Section 1.1, the term “internal research and development purposes” shall mean
any purpose that does not involve the financial support of, and grant of rights to, any third party commercial entity. 
  
 1.2 Effective Date. This Agreement shall be in full force and effect from the date first herein written and shall remain in effect in perpetuity
unless terminated by operation of law or by the acts of the Parties in accordance with Section 10 of this Agreement. 
  
 2. Ownership of the Licensed Patent 
  
 ORCHID acknowledges that nothing in this Agreement shall give ORCHID any right, title or interest in the Licensed Patent, other than in accordance with
the terms of the license granted hereunder. 
  
 3. Patent Use
and Ownership 
  
 3.1 Exclusive Ownership. ORCHID
acknowledges that SLU is the sole and exclusive owner of the Licensed Patent and ORCHID hereby agrees that it neither has had nor shall have any other rights with respect to such Licensed Patent except as provided herein. 
  
 3.2 Use of SLU Name. ORCHID agrees that it will not state or imply
either directly or indirectly that ORCHID or ORCHID’s activities, other than those permitted by this Agreement, are supported, endorsed, or sponsored by SLU and, upon the direction of SLU, shall issue express disclaimers to that effect. ORCHID
agrees not to use the name of SLU in business or affairs except for the use of the Licensed Patent as authorized herein, as required by law or as may be incidental to its financial and internal reports. 
  
 3.3 Use of Licensed Patent. ORCHID agrees it will use the Licensed
Patent only as authorized by this Agreement and will comply in all material respects with all appropriate local, state and national laws. 
  

 2 

 3.4 Agreements. On and after the date of this Agreement, SLU shall promptly provide ORCHID with
true and correct copies of all agreements pursuant to which the Licensed Patent is licensed to any third party (the “Existing Third Party Agreements”), including any agreements between SLU and Nanogen and SLU and Illumina; provided,
however, that SLU shall have the right to redact from such copies confidential financial or other information solely to the extent that any such redacted provisions do not bind ORCHID. It is agreed that all monies received by SLU under
the Existing Third Party Agreements on and after the Effective Date will be held by SLU for the benefit of Orchid and will be forwarded by SLU to ORCHID in a timely manner. 
  
 4. Filing, Prosecution And Maintenance Of Patent Rights 
  
 4.1 Patent Filing, Prosecution and Maintenance. Subject to the other terms of this Section 4, ORCHID shall be
responsible for maintaining, at its sole cost and expense, the Licensed Patent. Payment for maintenance fees incurred by SLU with respect to the Licensed Patent on and after the Effective Date shall be provided to SLU by ORCHID in a timely
manner upon ORCHID’s receipt of written notice of same from SLU and SLU shall promptly forward such payment onto the U.S. Patent and Trademark Office and shall provide ORCHID with reasonable evidence of same. SLU (a) will provide ORCHID with a
copy of any communication between SLU and the U.S. Patent Office concerning the Licensed Patent for review and comment reasonably in advance of any applicable filing deadline (which shall under no circumstances be in excess of thirty (30) days), and
(b) will keep ORCHID reasonably informed of the status of such communication, including, without limitation, (i) by providing ORCHID with copies of all communications received from or filed in patent office(s) with respect thereto, and (ii) by
providing ORCHID, a reasonable time prior to taking or failing to take any action that would affect the scope or validity thereof, with prior written notice of such proposed action or inaction so that ORCHID has a reasonable opportunity to review
and comment. 
  
 4.2 Notice of Infringement. If, during the
Term of this Agreement, either Party learns of any actual, alleged or threatened infringement by a Third Party of the Licensed Patent, such Party shall promptly notify the other Party and shall provide such other Party with available evidence of
such infringement. 
  
 4.3 Infringement of Patent Rights.
SLU shall have the first right (but not the obligation), at its own expense and with legal counsel of its own choice, to bring suit (or take other appropriate legal action) against any actual, alleged or threatened infringement by a Third Party of
the Licensed Patent either as a plaintiff or counterclaim plaintiff. ORCHID shall have the right, at its own expense, to be represented in any such action by SLU by counsel of ORCHID’s own choice; provided, however, that under no
circumstances shall the foregoing affect the right of SLU to control the suit as described in the first sentence of this Section 4.3. If SLU does not file any action or proceeding against such infringement within sixty (60) days after the later of
(a) SLU’s notice to ORCHID under Section 4.2 above, (b) ORCHID’s notice to SLU under Section 4.2 above, or (c) a written request from ORCHID to take action with respect to such infringement, then ORCHID shall have the right (but not the
obligation), at its own expense, to bring suit (or take other appropriate legal action) against such actual, alleged or threatened infringement, with legal counsel of its own choice. Any damages, monetary awards or other amounts recovered, whether
by judgment or settlement, pursuant to any suit, proceeding or other legal action taken under this Section 4.3, shall be applied as follows: 
  

 3 

 First, (a) if SLU exercises its first right as set forth above, then SLU will be reimbursed for its costs
and expenses (including reasonable attorneys’ fees and costs) incurred in prosecuting such enforcement action and (b) if SLU does not exercise its first right and ORCHID brings an action, then ORCHID will be reimbursed for its costs and
expenses (including reasonable attorneys’ fees and costs) in prosecuting such enforcement action; 
  
 Second, to ORCHID in reimbursement for damages, as set forth in 35 USC, Section 284, paragraph 1 (not to include enhanced damages under paragraph 2 of
Section 284 or attorneys’ fees under 35 USC, Section 285, if any), associated with Licensed Products as determined in the litigation to the extent there are monies available after the reimbursement to SLU or ORCHID as set forth above and in the
final sentence of this Section 4.3; and 
  
 Third, any amounts
remaining shall be allocated as follows: (a) if SLU is the Party bringing such suit or proceeding or taking such other legal action, seventy-five percent to SLU and twenty-five percent to ORCHID, (b) if ORCHID is the Party bringing such suit or
proceeding or taking such other legal action, one hundred percent (100%) to ORCHID. 
  
 If a Party brings any such action or proceeding hereunder, the other Party agrees to be joined as party plaintiff if necessary to prosecute such action or proceeding, and to give the Party bringing such action or
proceeding reasonable assistance and authority to file and prosecute the suit; provided, however, that neither Party shall be required to transfer any right, title or interest in or to any property to the other Party or any Third Party to confer
standing on a Party hereunder. In the event both Parties are necessary for the prosecution of the action, then both Party’s costs and expenses shall be paid first before ORCHID is reimbursed for damages as described above, if any, and any
monies remaining after ORCHID is so reimbursed will be split equally. 
  
 4.4 Third Party Patents. If any Third Party claims that a patent it owns or controls claims any aspect of the Licensed Patent or the manufacture, use or sale of any Licensed Product, the Party with notice of such claim
shall notify the other Party promptly, and the Parties shall as soon as practicable thereafter discuss in good faith regarding a response. 
  
 5. Payment 
  
 In consideration for the license granted herein, ORCHID agrees to make payments to SLU in accordance with the Settlement Agreement, which has been amended
by the Parties from time to time, which payment terms are herein incorporated by reference. Immediately upon the payment by ORCHID of the final installment payment amount due to SLU under the Settlement Agreement, SLU shall hereby be deemed to have
granted to ORCHID, without any further action of either Party hereunder, a fully-paid, perpetual and irrevocable license under the Licensed Patent to research, develop, make have made, use, have used, sell, offer for sale, have sold, import, have
imported, export and have exported Licensed Products, and to otherwise commercially exploit such Licensed Patent for any and all uses. 
  

 4 

 6. Representations and Warranties 
  
 Each of the Parties hereto makes the following representations and warranties to the other Party: 
  
 6.1 Consultation with Counsel. Each Party has either consulted or
been given the opportunity to consult with its own legal counsel concerning the terms of this Agreement, that it has not relied upon any representations, promises, inducements, or other assertions from the other party concerning the meaning of any
term of this Agreement, and that such Party understands fully the meaning and import of this Agreement. 
  
 6.2 Entire Agreement. Each Party, declares and represents that this Agreement contains the entire agreement reached between the Parties with
respect to the licensing of the Licensed Patent, and supersedes all prior agreements, understandings, negotiations and discussions of the Parties whether oral or written other than the agreements executed simultaneously herewith (e.g., Settlement
Agreement), portions of which have been incorporated herein pursuant to Section 5 above. 
  
 6.3 Authorized Representative. Each Party represents that it has caused its duly authorized representative to execute this Agreement on its behalf of the Party. 
  
 7. Further Representations and Warranties of SLU 
  
 SLU represents and warrants to ORCHID that to the best of its
knowledge (a) SLU has the full right and legal capacity to grant the rights to ORCHID pursuant to this Agreement; (b) SLU is the sole owner of the Licensed Patent and, other than with respect to the Existing Third Party Agreements, has not entered
into any agreement with any third party with respect to the Licensed Patent; and (c) there are no judicial or administrative actions, proceedings, claims or infringement, or investigations pending that question the right of SLU to use the Licensed
Patent or that questions the validity of the Licensed Patent. 
  
 8. Confidential Information 
  
 8.1 Disclosure
of Confidential Information. During the Term of this Agreement, each Party may disclose to the other Party confidential information. Such information of the disclosing Party hereunder, if so identified in writing by the disclosing Party to the
receiving Party either pursuant to this Section 8.1 or otherwise upon disclosure to the receiving Party followed within ten (10) days thereof with a writing, shall be “Confidential Information” of the disclosing Party. During the Term of
this Agreement and for a period of five (5) years thereafter, except as expressly permitted hereunder, the receiving Party shall keep confidential all such Confidential Information of the other Party and will not disclose such Confidential
Information of the other Party to Third Parties by publication or otherwise. Each Party further agrees not to use Confidential Information of the other Party for any purpose other than conducting research hereunder or exercising any rights granted
to it or reserved by it hereunder. Upon any 
  

 5 

 termination or expiration of this Agreement, upon request, a Party shall return to a requesting Party all copies of any
of such requesting Party’s Confidential Information, provided that its counsel may retain one copy for its legal files. Notwithstanding the foregoing, it is understood and agreed that the receiving Party’s obligations of confidentiality
and nonuse herein shall not apply to any information which: 
  
 (a) is, at the time of disclosure by the disclosing Party hereunder, or thereafter becomes, a part of the public domain or publicly known or available through no fault or negligence of the receiving Party or any of its Affiliates; or

  
 (b) was otherwise in the receiving Party’s lawful
possession prior to disclosure by the disclosing Party, as evidenced by a written document; or 
  
 (c) was independently discovered or developed by the receiving Party or any of its Affiliates, without use of the other Party’s Confidential Information, as can be demonstrated by competent proof; or 

 
 (d) is lawfully disclosed to the receiving Party or any of its Affiliates
on a non-confidential basis by a third party who is not in violation of an obligation of confidentiality to the disclosing Party relative to such information. 
  

Each Party may disclose information to the extent such disclosure is reasonably necessary in (i) filing for a Certificate of Re-Examination and/or maintaining the
Licensed Patent, or (ii) filing, prosecuting or defending litigation or (iii) complying with applicable laws, regulations or court orders; provided, however, that if a Party is required to make any such disclosure of the other
Party’s Confidential Information or the terms of this Agreement, it will give reasonable advance notice to the other Party of such disclosure requirement and will use reasonable efforts to assist such other Party in efforts to secure
confidential treatment of such information required to be disclosed. 
  
 8.2 Publicity. A Party shall not use the name of the other Party in any publicity or advertising and may not issue a press release or otherwise publicize or disclose any information related to the other Party’s activities under
this Agreement or the terms or conditions hereof, without the prior written consent of the other Party. Nothing shall prohibit a Party from making any disclosures to the extent deemed necessary under applicable federal or state securities laws or
any rule or regulation of any nationally recognized securities exchange; provided, however, that such Party shall provide written notice thereof to the other Party, consult with the other Party with respect to such disclosure and
provide the other Party sufficient opportunity to comment on or object to any such disclosure or to request confidential treatment thereof. 
  
 9. Indemnification 
  
 9.1 Indemnification by ORCHID. ORCHID will indemnify SLU against any liability and hold SLU harmless from and pay any loss, damage, cost, expense,
fine or penalty (including, without limitation, legal fees and disbursements, court costs and the cost of appellate proceedings) (“Damages”), regardless of whether the same is also indemnified against by any 
  

 6 

 other person, which SLU in any way incurs arising out of or in connection with (a) any breach by ORCHID of its
representations under this Agreement, or (b) the manufacture, use or sale by ORCHID of Licensed Products. 
  
 9.2 Indemnification by SLU. Subject to Section 9.1 above, SLU shall indemnify, defend and hold harmless ORCHID, its Affiliates and their respective
directors, officers, employees, and agents, and their respective successors, heirs and assigns ( the “ORCHID Indemnitees”), from and against any Damages incurred by or imposed upon such ORCHID Indemnitees, or any of them, which ORCHID in
any way incurs arising out of or in connection with any breach by SLU of its representations under this Agreement. 
  
 10. Termination 
  
 10.1 Termination upon Default. Subject to the other terms of this Agreement, this Agreement and the rights granted herein may be terminated by either Party upon any breach by the other party of any material
obligation or condition, effective ten (10) days after giving written notice to the breaching Party of such termination in the case of a payment breach and forty-five (45) days after giving written notice to the breaching Party of such termination
in the case of any other breach, which notice shall describe such breach in reasonable detail. The foregoing notwithstanding, if such default or breach is cured or shown to be non-existent within the aforesaid ten (10) or forty-five (45) day period,
the notice shall be automatically withdrawn and of no effect. 
  
 10.2 Grounds for Immediate Termination. SLU shall have the right to immediately terminate this Agreement by giving written notice to ORCHID if ORCHID does any of the following: 
  

	 	(1)	files a petition of bankruptcy or is adjudicated as bankrupt or insolvent, or makes an assignment for the benefit of creditors, or an arrangement pursuant to any bankruptcy law, or
if the ORCHID discontinues its business or a receiver is appointed for ORCHID for ORCHID’s business and such receiver is not discharged within sixty (60) days; or 

  

	 	(2)	ceases to operate as a business. 

  
 10.3 Termination by ORCHID. ORCHID may terminate this Agreement at any time upon thirty (30) days prior written notice to SLU, but agrees that any
termination of this Agreement shall not relieve ORCHID of payments to be made pursuant to Section 5 hereof. 
  
 10.4 Injunctive Relief. Each Party hereto acknowledges that money damages alone are inadequate to compensate the other Party for any breach by a
Party of this Agreement. Therefore, in the event of a breach or threatened breach of any provision of this Agreement by a Party, the non-breaching party may, in addition to all other remedies, immediately obtain and enforce injunctive relief
prohibiting the breach or compelling specific performance. 
  

 7 

 10.5 Section 365(n). All licenses granted under this Agreement are deemed to be, for purposes of
Section 365(n) of the U.S. Bankruptcy Code, licenses of right to “intellectual property” as defined in Section 101 of such Code. The Parties agree that the licensee may fully exercise all of its rights and elections under the U.S.
Bankruptcy Code, regardless of whether either Party files for bankruptcy in the United States or other jurisdiction. The Parties further agree that, in the event a licensee elects to retain its rights as a licensee under such Code, the licensee
shall be entitled to complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to the licensee not later than: 
  
 (a) the commencement of bankruptcy proceedings against the licensor, upon
written request, unless the licensor elects to perform its obligations under the Agreement, or 
  
 (b) if not delivered under Section 8.19.1 above, upon the rejection of this Agreement by or on behalf of the licensor, upon written request. 
  
 11. Effect of Termination 
  
 11.1 Obligations upon Termination by SLU. Upon termination of this Agreement by SLU in accordance with Section 10.1 or 10.2 above, ORCHID agrees
to: 
  

	 	(1)	immediately discontinue the use of the Licensed Patent. 

  

	 	(2)	immediately return to SLU at ORCHID’s cost all materials relating to the Licensed Patent including, but not limited to, all artwork, color separations, prototypes and the like.

  
 12. Miscellaneous Provisions 

 
 12.1 Captions. Captions contained in this Agreement have been
inserted herein only as a matter of convenience and in no way define, limit, extend or describe the scope of this Agreement or the intent of any provision hereof. 
  
 12.2 Counterparts. This Agreement may be executed by the Parties on any number of separate counterparts and via
facsimile copies, and all such counterparts and facsimile copies so executed constitute one agreement binding on all the Parties notwithstanding that all the Parties are not signatories to the same counterpart. 
  
 12.3 Future Amendments. Except as otherwise set forth in this
Agreement, this Agreement may only be modified or amended by a written instrument signed by both Parties. 
  
 12.4 Governing Law. This Agreement and the rights and obligations of the Parties hereunder shall be governed by, interpreted and construed in
accordance with the laws of the State of Missouri and the federal laws of the United States. 
  

 8 

 12.5 Jurisdiction. ANY LEGAL ACTION OR PROCEEDING WITH RESPECT TO THIS AGREEMENT OR ANY DOCUMENT
RELATED HERETO MAY BE BROUGHT IN THE COURTS OF THE STATE OF MISSOURI OR ANY COURT OF THE UNITED STATES OF AMERICA FOR THE EASTERN DISTRICT OF MISSOURI AND, BY EXECUTION AND DELIVERY OF THIS AGREEMENT, EACH PARTY HEREBY ACCEPTS FOR ITSELF AND IN
RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, THE JURISDICTION OF SUCH COURTS. THE PARTIES IRREVOCABLY WAIVE ANY OBJECTION, INCLUDING ANY OBJECTION TO THE LAYING OF VENUE OR BASED ON THE GROUNDS OF FORUM NON CONVENIENS, WHICH ANY OF THEM
MAY NOW OR HEREAFTER HAVE TO THE BRINGING OF ANY SUCH ACTION OR PROCEEDING IN SUCH RESPECTIVE JURISDICTIONS. EACH PARTY IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS OF ANY OF SUCH COURTS IN ANY SUCH ACTION OR PROCEEDING BY THE MAILING OF COPIES
THEREOF BY REGISTERED OR CERTIFIED MAIL, POSTAGE PREPAID, TO EACH OF THE OTHER PARTIES AT ITS ADDRESS PROVIDED HEREIN, SUCH SERVICE TO BECOME EFFECTIVE 30 DAYS AFTER SUCH MAILING. 
  
 12.6 Agreement. Neither this Agreement nor any right or obligation hereunder may be assigned, delegated or otherwise
transferred, in whole or part, by either Party without the prior express written consent of the other; provided, however, that either Party may, without the written consent of the other, assign this Agreement and its rights and delegate its
obligations hereunder to its Affiliates, or in connection with the transfer or sale of all or substantially all of such Party’s assets or business related to this Agreement, or in the event of its merger, consolidation, change in control or
similar transaction. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment in violation of this Section 12.6 shall be void. The terms and conditions of this Agreement shall be binding upon
and inure to the benefit of the permitted successors and assigns of the Parties. 
  
 12.7 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties hereto, and their respective successors and assigns and any persons claiming by, through or under them.

  
 12.8 Void or Unenforceable Clauses. Should any part,
term or provision of this Agreement be declared or determined by any court to be illegal or invalid, the validity of the remaining parts, terms and provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be
deemed not to be part of this Agreement and the terms of this Agreement shall be equitably adjusted so as to compensate the appropriate party for any consideration lost because of the elimination of such clause or clauses. It is the intent and
expectation of each of the parties that each provision of this Agreement will be honored, carried out and enforced as written. Consequently, each of the parties agree that any provision of this Agreement sought to be enforced in any proceeding
hereunder shall, at the election of the party seeking enforcement and notwithstanding the availability of an adequate remedy at law, be enforced by specific performance. 
  

 9 

 12.9 Waiver. Any waiver by either Party of any breach by the other shall not be deemed to be a
waiver of any other or subsequent breach nor an estoppel to enforce its rights in respect of any other or subsequent breach. This Agreement shall not be waived, altered or rescinded, in whole or in part, except by a writing signed by the Party
making the waiver or an officer of such party as the case may be. 
  
 12.10 Survival. The representations and warranties in Section 5, and indemnification provisions in Section 6, contained herein survive the execution and delivery of this Agreement. 
  
 12.11 Compliance With Government Reporting. ORCHID acknowledges that SLU has
and will have in the future certain reporting obligations to the NIH related to the ‘710 Patent. ORCHID, therefore, agrees to provide SLU, upon SLU’s request, all information within ORCHID’s control related to the ‘710 Patent
reasonably necessary for SLU to comply with such reporting requirements. All such information requested by SLU shall be provided by ORCHID in a reasonable and timely manner and shall be deemed to be Confidential Information of ORCHID, subject to
Section 8.1 of this Agreement. Such information that may be requested includes, but is not limited to, patent utilization information, such as product sales and corresponding revenue information, and other information related to invention reporting
requirements, all solely to the extent reasonably related to the ‘710 Patent. 
  
 [Remainder of page intentionally left blank] 
  

 10 

 IN WITNESS WHEREOF, the parties hereto have executed this Exclusive Patent License Agreement on the date
first written above. 
  

									
	 SAINT LOUIS UNIVERSITY
	 	 	 	 ORCHID BIOSCIENCES, INC.

					
	 By:
	 	     /s/

	 	 	 	 By:
	 	     /s/

	 Name:
	 	 Robert N. Altholtz

	 	 	 	 Name:
	 	 Paul J. Kelly

	 Title:
	 	 Vice President

	 	 	 	 Title:
	 	 CEO

  
  

 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00063-of-00352.parquet"}]]